NEW HAVEN, Conn., Dec. 8, 2011 /PRNewswire/ -- Cenestra Health announces that the U.S. Patent and Trademark Office (the "USPTO") has issued a new U.S. patent, No. 8,071,646 (the "'646 patent"), that protects and provides Cenestra with exclusivity for highly pure formulations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in ratios ranging from about 3.5:1 to about 5:1. The '646 patent provides exclusivity for these EPA:DHA ratios in compositions with > 84% omega-3s as the active ingredient. The '646 patent also provides exclusive rights to a number of uses for these superior EPA:DHA ratios.
While Cenestra's previously awarded U.S. patent No. 7,652,068 secured Cenestra's intellectual property on a composition of highly pure ethyl ester forms omega-3 formulations in EPA:DHA ratios of 4.1:1, the '646 patent greatly broadens the opportunity to develop highly unique and best in class EPA:DHA prescription products. Both patents place Cenestra in a unique position to have therapeutically superior, patent protected products for treatment of diseases such as cardiovascular disease and depression.
"We are pleased that the USPTO recognized the novelty of these specific ratios of EPA to DHA that Cenestra discovered. Cenestra's research shows that there are clearly superior ratios and dosages of these bioactive lipids for specified applications. We hope to bring Cenestra's innovative products to patients afflicted with the illnesses that these specific ratios of omega-3s are optimized to treat," said Louis Sanfilippo, M.D., Assistant Clinical Professor at Yale School of Medicine and Managing Director of Cenestra Health.
"We believe that with the granting of the '646 patent, Cenestra finds itself in the unique position as the only high purity omega-3 company with straight-forward composition patents with long patent life remaining. We believe this will allow Cenestra the ability to garner considerable investment in product development, and sales and marketing. From the data Cenestra has generated to date, we expect the products developed under the Cenestra patents will confer superior efficacy to those currently on the market or announced to be in development," stated Dr. Sanfilippo.
About Cenestra, LLC (D/B/A Cenestra Health)
Cenestra Health is a privately-held and unleveraged biopharmaceutical company based in New Haven, Connecticut. Cenestra Health was founded in 2005 to formulate, develop and market "best-in-class" proprietary natural products with applications in the OTC, medical food and pharmaceutical markets. Cenestra Health is focused on the clinical development of its late stage clinical drug candidates for the treatment of dyslipidemias and central nervous system disorders. Cenestra Health is planning to initiate Phase 3 registrational trials in early 2012.
About Omega-3 Essential Fatty Acids
Omega-3 fatty acids are considered "essential" fatty acids (EFAs) as they are necessary to human health but cannot be produced by the body. The two major health promoting omega-3 polyunsaturated fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA and DHA have been shown to promote good physical and emotional health, reduce the risk of cardiovascular disease, and exert powerful anti-inflammatory effects. Omega-3 prescriptions in the United States alone accounted for over $1 billion dollars in sales in 2010.
Statements made in this press release should not to be construed as making any specific claim or claims in the diagnosis, prevention or treatment of any disease or disorder but may relate to historical facts and information that reflect forward looking statements based on Cenestra Health's intellectual property and scientific data.
US Patent No. 7,652,068/Omega-3 Fatty Acid Formulations
US Patent No. 8,071,646/Omega-3 Fatty Acid Formulations
|SOURCE Cenestra Health|
Copyright©2010 PR Newswire.
All rights reserved